Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics

Jurjen S. Lagas, Alfred H. Schinkel(Oncode Institute), Olaf van Tellingen(Dutch Cancer Society), Hilde Rosing(The Netherlands Cancer Institute), Maria L.H. Vlaming(Oncode Institute), Els Wagenaar(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Robert S. Jansen(Radboud University Nijmegen)
Clinical Cancer Research
October 15, 2006
10.1158/1078-0432.ccr-06-1352
Cited by 90

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688